4.89
-0.96 (-16.41%)
| Penutupan Terdahulu | 5.85 |
| Buka | 5.64 |
| Jumlah Dagangan | 608,808 |
| Purata Dagangan (3B) | 904,774 |
| Modal Pasaran | 33,385,750 |
| Harga / Jualan (P/S) | 3.41 |
| Harga / Buku (P/B) | 2.07 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Aug 2025 - 18 Aug 2025 |
| Margin Operasi (TTM) | -1,378.09% |
| EPS Cair (TTM) | -12.07 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5,268.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 13.66% |
| Nisbah Semasa (MRQ) | 1.03 |
| Aliran Tunai Operasi (OCF TTM) | -11.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.73 M |
| Pulangan Atas Aset (ROA TTM) | -176.75% |
| Pulangan Atas Ekuiti (ROE TTM) | -714.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Sonnet BioTherapeutics Holdings | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | -1.64 |
|
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.53% |
| % Dimiliki oleh Institusi | 5.24% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |